ClinicalTrials.gg
CompletedNCT00701883MBX-8025Updated Jun 12, 2015

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

A Phase 2 interventional study of Placebo and MBX-8025 in Hyperlipidemia, sponsored by Gilead Sciences. Completed at 28 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-12.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies testing atorvastatin in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Atorvastatin · Hyperlipidemias.

Enrollment
14th of 37
183 · median 99
Started
2007
with 3 others
Phase 2
5 of 37
none open now
Registered
18th of 37
by date

Among the 37 studies testing atorvastatin in Hyperlipidemias, this one is the 14th largest by enrollment, is one of 4 that started in 2007, is one of 5 in phase 2, and was the 18th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 37 studies testing atorvastatin in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 37 studies testing atorvastatin in Hyperlipidemias as a file.
02

Study summary

A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy, safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin resistance and obesity in overweight, hyperlipidemic patients, both as monotherapy and in combination with Atorvastatin

Total participation for each patient is approximately 16-17 weeks, which may include up to a 2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up. During the run-in period patients taking statins, statin combination or Zetia will undergo a 'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their same diet prior to entering the study). They will be asked to defer initiating any weight loss diets or meaningful changes in their activity level until after they have completed the study. Once randomized into the double blind study, patients will visit the clinic every two weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the double-blind study medication will be discontinued. Patients will attend a follow up visit two weeks after their final dose for safety evaluation.

Read the detailed description

Total participation for each patient is approximately 16-17 weeks, which may include up to a 2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up. During the run-in period patients taking statins, statin combination or Zetia will undergo a 'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their same diet prior to entering the study). They will be asked to defer initiating any weight loss diets or meaningful changes in their activity level until after they have completed the study. Once randomized into the double blind study, patients will visit the clinic every two weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the double-blind study medication will be discontinued. Patients will attend a follow up visit two weeks after their final dose for safety evaluation.

03

Conditions studied

  • Hyperlipidemia

Keywords

  • Cholesterol
  • Hyperlipidemia
  • HDL
  • LDL
  • Triglycerides
  • Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-75 years
  • Female patients must not be pregnant or breast-feeding
  • Patients must be moderately overweight
  • All patients must have abnormal cholesterol levels or a history of abnormal cholesterol levels as defined by the protocol.
  • Patients taking medication to lower their cholesterol must be willing, in some cases, to discontinue their medications during the study Stable weight (a history of increasing or decreasing no more than 6.6 lbs [3 kg]) for at least 2 months prior to the study;

Exclusion criteria

Exclusion Criteria

  • Cancer or a history of a cancer within 5 years before screening, other than some skin cancers
  • Patients planning elective surgery during the study
  • Patients with a history of diabetes mellitus at study onset
  • History of intolerance to, or adverse effect from atorvastatin
  • History of weight loss due to stomach bypass or eating disorder
  • All patients may not have had a stroke, , an acute myocardial infarction, angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy) within 5 months of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
183 participants (actual)

Study arms

  • Placebo comparator
    Placebo/Placebo

    Drug: Placebo

  • Experimental
    MBX-8025 50 mg/Placebo

    Drug: Placebo · Drug: MBX-8025

  • Experimental
    MBX-8025 100 mg/Placebo

    Drug: Placebo · Drug: MBX-8025

  • Active comparator
    Placebo/Atorvastatin 20 mg

    Drug: Placebo · Drug: Atorvastatin

  • Experimental
    MBX-8025 50 mg/Atorvastatin 20 mg

    Drug: Atorvastatin · Drug: MBX-8025

  • Experimental
    MBX-8025 100 mg/Atorvastatin 20 mg

    Drug: Atorvastatin · Drug: MBX-8025

Interventions

  • DrugPlacebo

    2 capsules, once a day for 8 weeks

  • 2 capsules, once daily for 8 weeks

  • 2 capsule, once daily for 8 weeks

  • 2 capsules, once daily for 8 weeks

  • 2 capsules, once daily for 8 weeks

  • 2 capsules, once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Lipid levels will be measured in patients with hyperlipidemia to assess the benefits of the investigational drug

    Time frame: 8 week treatment period

07

Study locations

28 sites
  • Radiant Research
    Birmingham, Alabama 35209, United States
  • Anasazi Internal Medicine Research
    Phoenix, Arizona 85032, United States
  • Diabetes/Lipid Management and Research Center
    Huntington Beach, California 92648, United States
  • Radiant Research
    Santa Rosa, California 95405, United States
  • Clinical Research Consulting LLC
    Milford, Connecticut 06460, United States
  • Genesis Research International
    Indianapolis, Indiana 46260, United States
  • Midwest Institute for Clinical Research Inc.
    Indianapolis, Indiana 46260, United States
  • L-Marc Research Center
    Louisville, Kentucky 40213, United States
  • Maine Research Associates
    Auburn, Maine 46260, United States
  • Health Trends Research LLC
    Baltimore, Maryland 21209, United States
  • Troy Internal Medicine Research
    Troy, Michigan 48098, United States
  • Bridgewater Medical Group
    Bridgewater, New Jersey 08807, United States
  • Clifton-Wallington Medical Group
    Clifton, New Jersey 07013, United States
  • Rochester Clinical Research
    Albuquerque, New Mexico 87108, United States
  • United Medical Associates P.C.
    Binghamton, New York 13901, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • Southgate Medical Group
    West Seneca, New York 14224, United States
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
  • PharmQuest
    Greensboro, North Carolina 27401, United States
  • Crescent Medical Research
    Salisbury, North Carolina 28144, United States
  • Piedmont Medical Research Associates
    Winston-Salem, North Carolina 27103, United States
  • PHA-Adult Medicine
    Philadelphia, Pennsylvania 19146, United States
  • Radiant Research
    Greer, South Carolina 29651, United States
  • Tricities Medical Research
    Bristol, Tennessee 37620, United States
  • Holston Medical Group Clinical Research
    Kingsport, Tennessee 37660, United States
  • Dallas Diabetes and Endocrine Center
    Dallas, Texas 75230, United States
  • Diabetes and Glandular Disease Research
    San Antonio, Texas 78229, United States
  • Walla Walla Clinic
    Walla Walla, Washington 99362, United States
08

References and documents

Publications

  • Choi YJ, Roberts BK, Wang X, Geaney JC, Naim S, Wojnoonski K, Karpf DB, Krauss RM. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6. doi: 10.1016/j.atherosclerosis.2011.10.029. Epub 2011 Nov 16. PubMed 22169113 ↗
  • Bays HE, Schwartz S, Littlejohn T 3rd, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97. doi: 10.1210/jc.2011-1061. Epub 2011 Jul 13. PubMed 21752880 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2008
First posted
Jun 19, 2008
Start
Aug 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results delay requested
Feb 16, 2015
Last update
Jun 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00701883
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 19, 2008
Start date
Aug 2007
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Jun 12, 2015

Study contacts

Brian Roberts, M.D.
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Seladelpar · Atorvastatin

Start the discussion